Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?

Inzucchi SE, Fitchett D, Jurišić-Eržen D, Woo V, Hantel S, Janista C, Kaspers S, George JT, Zinman B; EMPA-REG OUTCOME® Investigators.

Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13938. [Epub ahead of print]

PMID:
31789445
2.

Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.

Lourenco AR, Ban Y, Crowley MJ, Lee SB, Ramchandani D, Du W, Elemento O, George JT, Jolly MK, Levine H, Sheng J, Wong STC, Altorki NK, Gao D.

Cancer Res. 2019 Nov 8. pii: canres.1427.2019. doi: 10.1158/0008-5472.CAN-19-1427. [Epub ahead of print]

PMID:
31704888
3.

Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis.

Nihan Kilinc A, Sugiyama N, Reddy Kalathur RK, Antoniadis H, Birogul H, Ishay-Ronen D, George JT, Levine H, Kumar Jolly M, Christofori G.

Oncogene. 2019 Oct 30. doi: 10.1038/s41388-019-1081-2. [Epub ahead of print]

PMID:
31666683
4.

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.

Thangavel H, Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV.

J Clin Med. 2019 Oct 24;8(11). pii: E1772. doi: 10.3390/jcm8111772.

5.

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.

Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kiš SG, Kaspers S, George JT, Fitchett D.

Age Ageing. 2019 Nov 1;48(6):859-866. doi: 10.1093/ageing/afz096.

PMID:
31579904
6.

A fatal case of levamisole induced bone marrow failure.

George JT, Janeela AM, Sigamani E, Mathuram AJ.

BMJ Case Rep. 2019 Sep 30;12(9). pii: e231167. doi: 10.1136/bcr-2019-231167.

PMID:
31570359
7.

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N; CAROLINA Investigators.

JAMA. 2019 Sep 19. doi: 10.1001/jama.2019.13772. [Epub ahead of print]

PMID:
31536101
8.

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.

Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE.

Eur Heart J. 2019 Aug 31. pii: ehz621. doi: 10.1093/eurheartj/ehz621. [Epub ahead of print]

PMID:
31504427
9.

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.

Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE; CARMELINA Investigators.

Diabetes Care. 2019 Oct;42(10):1930-1938. doi: 10.2337/dc19-0783. Epub 2019 Aug 9.

PMID:
31399442
10.

NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype.

Bocci F, Tripathi SC, Vilchez Mercedes SA, George JT, Casabar JP, Wong PK, Hanash SM, Levine H, Onuchic JN, Jolly MK.

Integr Biol (Camb). 2019 Jun 1;11(6):251-263. doi: 10.1093/intbio/zyz021.

11.

Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.

Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, Kandaswamy P, Ruffolo A.

Diabet Med. 2019 Nov;36(11):1494-1502. doi: 10.1111/dme.14076. Epub 2019 Jul 23.

12.

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.

Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, Pang C, Wood R, Kinduryte O, George JT, Marquard J, Soleymanlou N.

Diabetes Care. 2019 Sep;42(9):1716-1723. doi: 10.2337/dc19-0548. Epub 2019 Jun 8.

PMID:
31177179
13.

Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer.

Jolly MK, Preca BT, Tripathi SC, Jia D, George JT, Hanash SM, Brabletz T, Stemmler MP, Maurer J, Levine H.

APL Bioeng. 2018 Aug 22;2(3):031908. doi: 10.1063/1.5024874. eCollection 2018 Sep.

14.

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.

PMID:
30885684
15.

E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms.

Jolly MK, Ware KE, Xu S, Gilja S, Shetler S, Yang Y, Wang X, Austin RG, Runyambo D, Hish AJ, Bartholf DeWitt S, George JT, Kreulen RT, Boss MK, Lazarides AL, Kerr DL, Gerber DG, Sivaraj D, Armstrong AJ, Dewhirst MW, Eward WC, Levine H, Somarelli JA.

Mol Cancer Res. 2019 Jun;17(6):1391-1402. doi: 10.1158/1541-7786.MCR-18-0763. Epub 2019 Mar 12.

16.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
17.

Visceral leishmaniasis with haemophagocytic lymphohistiocytosis.

George JT, Sadiq M, Sigamani E, Mathuram AJ.

BMJ Case Rep. 2019 Feb 13;12(2). pii: e226361. doi: 10.1136/bcr-2018-226361.

PMID:
30765439
18.

Spleen Tyrosine Kinase-Mediated Autophagy Is Required for Epithelial-Mesenchymal Plasticity and Metastasis in Breast Cancer.

Shinde A, Hardy SD, Kim D, Akhand SS, Jolly MK, Wang WH, Anderson JC, Khodadadi RB, Brown WS, George JT, Liu S, Wan J, Levine H, Willey CD, Krusemark CJ, Geahlen RL, Wendt MK.

Cancer Res. 2019 Apr 15;79(8):1831-1843. doi: 10.1158/0008-5472.CAN-18-2636. Epub 2019 Feb 7.

PMID:
30733195
19.

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment.

Li X, Jolly MK, George JT, Pienta KJ, Levine H.

Front Oncol. 2019 Jan 23;9:10. doi: 10.3389/fonc.2019.00010. eCollection 2019.

20.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
21.

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT.

Diabetes Obes Metab. 2019 May;21(5):1073-1078. doi: 10.1111/dom.13645. Epub 2019 Mar 12.

PMID:
30690856
22.

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.

Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, George JT, Fitchett D.

Diabetes Care. 2019 Mar;42(3):e42-e44. doi: 10.2337/dc18-1959. Epub 2019 Jan 23. No abstract available.

PMID:
30674547
23.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

24.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
25.

Testing the gene expression classification of the EMT spectrum.

Jia D, George JT, Tripathi SC, Kundnani DL, Lu M, Hanash SM, Onuchic JN, Jolly MK, Levine H.

Phys Biol. 2019 Jan 18;16(2):025002. doi: 10.1088/1478-3975/aaf8d4.

PMID:
30557866
26.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

27.

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F.

Eur Heart J. 2019 Sep 7;40(34):2907-2919. doi: 10.1093/eurheartj/ehy677. No abstract available.

PMID:
30445605
28.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

29.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
30.

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B.

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810. No abstract available.

PMID:
30354516
31.

Correlation between the outcomes and severity of diabetic ketoacidosis: A retrospective pilot study.

George JT, Mishra AK, Iyadurai R.

J Family Med Prim Care. 2018 Jul-Aug;7(4):787-790. doi: 10.4103/jfmpc.jfmpc_116_18.

32.

Stochastic modeling of tumor progression and immune evasion.

George JT, Levine H.

J Theor Biol. 2018 Dec 7;458:148-155. doi: 10.1016/j.jtbi.2018.09.012. Epub 2018 Sep 12.

PMID:
30218648
33.

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials.

Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM.

JACC Heart Fail. 2018 Aug;6(8):619-632. doi: 10.1016/j.jchf.2018.06.008. Review.

34.

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Sattar N, Fitchett D, Hantel S, George JT, Zinman B.

Diabetologia. 2018 Oct;61(10):2155-2163. doi: 10.1007/s00125-018-4702-3. Epub 2018 Jul 31.

35.

A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling.

Bocci F, Jolly MK, George JT, Levine H, Onuchic JN.

Oncotarget. 2018 Jul 6;9(52):29906-29920. doi: 10.18632/oncotarget.25692. eCollection 2018 Jul 6.

36.

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B.

Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.

37.

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D; EMPA-REG OUTCOME® investigators.

Diabetologia. 2018 Jul;61(7):1522-1527. doi: 10.1007/s00125-018-4630-2. Epub 2018 Apr 30.

PMID:
29713728
38.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

39.

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.

Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022. No abstract available.

40.

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM.

Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.

PMID:
29203583
41.

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.

Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, George JT, Zinman B.

Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13. No abstract available.

PMID:
29133602
42.

Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women.

Skorupskaite K, George JT, Veldhuis JD, Anderson RA.

J Clin Endocrinol Metab. 2018 Jan 1;103(1):95-104. doi: 10.1210/jc.2017-01306.

43.

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511.

PMID:
29020355
44.

Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.

George JT, Jolly MK, Xu S, Somarelli JA, Levine H.

Cancer Res. 2017 Nov 15;77(22):6415-6428. doi: 10.1158/0008-5472.CAN-16-3521. Epub 2017 Sep 25.

45.

Bladder cancer in the EMPA-REG OUTCOME trial.

Kohler S, Lee J, George JT, Inzucchi SE, Zinman B.

Diabetologia. 2017 Dec;60(12):2534-2535. doi: 10.1007/s00125-017-4430-0. Epub 2017 Sep 14. No abstract available.

46.

Effects of thymic selection on T cell recognition of foreign and tumor antigenic peptides.

George JT, Kessler DA, Levine H.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7875-E7881. doi: 10.1073/pnas.1708573114. Epub 2017 Sep 5.

47.

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program.

Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Review.

48.

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Marx N, McGuire DK, Perkovic V, Woerle HJ, Broedl UC, von Eynatten M, George JT, Rosenstock J.

Diabetes Care. 2017 Sep;40(9):1144-1151. doi: 10.2337/dc17-0068.

PMID:
28830955
49.

Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA.

Clin Endocrinol (Oxf). 2017 Dec;87(6):748-756. doi: 10.1111/cen.13445. Epub 2017 Sep 5.

PMID:
28802064
50.

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke - Reply.

Kaku K, Lee J, Kaspers S, Woerle HJ, George JT.

Circ J. 2017 May 25;81(6):899. doi: 10.1253/circj.CJ-17-0395. Epub 2017 May 10. No abstract available.

Supplemental Content

Loading ...
Support Center